We are pleased to announce our newest paper in Cancers MDPI is now published online! This work unveils the potential of Apmonia Therapeutics’ lead candidate TAX2 (AP-01)
Apmonia Therapeutics’ lead program (AP-01 or TAX2) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet
We are extremely pleased and enthusiastic that we can count upon the valued support of Business Angels Marne-Ardennes (BAMA, former Reims Business Angels)! This enables Apmonia Therapeutics to
Check out Apmonia Therapeutics’ press release on the company’s corporate organization and i-Lab innovation award.#deeptech #biotech #cancer #reims
We feel very honored to be recipient of the i-Lab 2020 award. Support given to our ambitious project by Ministère de l’Enseignement Supérieur et de
We are thrilled to announce that Institut national du cancer (INCa) will provide financial support to a unique industry-academic R&D partnership gathering together Apmonia Therapeutics,
